Drug Profile
Simmitecan - HaiHe Biopharma
Alternative Names: Simmitecan hydrochlorideLatest Information Update: 22 Mar 2022
Price :
$50
*
At a glance
- Originator ShangHai HaiHe Pharmaceutical
- Developer HaiHe Biopharma
- Class Alkaloids; Antineoplastics; Camptothecins; Esters; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors; Hypoxia-inducible factor 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Neuroendocrine tumours
- Phase II Colorectal cancer
- No development reported Solid tumours
Most Recent Events
- 22 Mar 2022 Phase-III development is ongoing in Neuroendocrine tumours (Late-stage disease, Metastatic disease) in China (IV) (NCT03992911)
- 29 May 2020 Adverse events and efficacy data from a phase I trial in Solid tumours and Colorectal cancer presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)
- 28 Nov 2019 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in China (IV, Infusion)